Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

Abstract

Precision medicine focuses on DNA abnormalities, but not all tumors have tractable genomic alterations. The WINTHER trial () navigated patients to therapy on the basis of fresh biopsy-derived DNA sequencing (arm A; 236 gene panel) or RNA expression (arm B; comparing tumor to normal). The clinical management committee (investigators from five countries) recommended therapies, prioritizing genomic matches; physicians determined the therapy given. Matching scores were calculated post-hoc for each patient, according to drugs received: for DNA, the number of alterations matched divided by the total alteration number; for RNA, expression-matched drug ranks. Overall, 303 patients consented; 107 (35%; 69 in arm A and 38 in arm B) were evaluable for therapy. The median number of previous therapies was three. The most common diagnoses were colon, head and neck, and lung cancers. Among the 107 patients, the rate of stable disease ≥6 months and partial or complete response was 26.2% (arm A: 23.2%; arm B: 31.6% (P=0.37)). The patient proportion with WINTHER versus previous therapy progression-free survival ratio of >1.5 was 22.4%, which did not meet the pre-specified primary end point. Fewer previous therapies, better performance status and higher matching score correlated with longer progression-free survival (all P<0.05, multivariate). Our study shows that genomic and transcriptomic profiling are both useful for improving therapy recommendations and patient outcome, and expands personalized cancer treatment.

Multiomics Characterization of Potential Therapeutic Vulnerabilities in Low-grade Serous Ovarian Carcinoma

“…Recently, Schutte et al showed integration of genomic and transcriptomic data significantly outperformed less comprehensive analysis in the identification of clinically relevant molecular alterations [65]. The combination of DNA and RNA-based analyses have shown to serve as mutual controls for verifying potential findings [21]. As LGSOC is a rare cancer, model systems and patient samples are limited.…”

“…To accelerate progress in precision oncology, future research must go beyond the genomic aberrations found in tumors and explore the more complex aspects of tumor biology. Thus, multiomics tumor profiling with data integration analysis [21] provides a new window of opportunity for the identification of molecular disease drivers leading to more successful drug therapies.…”

Whole exome precision oncology targeting synthetic lethal vulnerabilities across the tumor transcriptome

“…There have been significant advances in precision oncology, with an increasing adoption of sequencing tests that identify targetable mutations in cancer driver genes. Aiming to complement these efforts by considering genome-wide tumor alterations at additional "-omics" layers, recent studies have begun to explore the utilization of transcriptomics data to guide cancer patients' treatment [1][2][3][4] . These studies have reported encouraging results, testifying to the potential of such approaches to complement mutation panels and increase the likelihood that patients will benefit from genomics-guided, precision treatments.…”

Potential mechanisms of action of celastrol against rheumatoid arthritis: transcriptomic and proteomic analysis

“…High-throughput profiling of transcripts and proteins can identify genes whose expression is altered by a drug of interest [19][20][21]. Transcriptomic profiling on its own does not take into account post-transcriptional modifications, efficiency of translation or transcript turnover, all of which can affect activity of the encoded proteins [22,23]. Therefore combining transcriptomic and proteomic profiling may be more effective for identifying drug-induced changes [24][25][26].…”